

Impact of Hypertension and Antihypertensive Treatment on COVID-19 Severity: A Retrospective Observational Study in Ternopil Region, Ukraine [Corrigendum]

Hrebenyk M, Maslii S, Shevchuk O, Komorovsky R, Korda M. *Ther Clin Risk Manag.* 2025;21:995—1007.

The authors have advised there is an error on page 1000, paragraph 3, several correlation coefficients were printed without leading zeros (eg, $r = 238$ instead of $r = 0.238$). This was a formatting oversight, which does not affect the interpretation of the data. The correct text should read as follows.

Even though area of lung damage was not significantly different in studied groups we found weak correlation between the size of damaged area and COVID-19 severity ($r=0.238$, $p<0.001$), HP complications ($r=0.276$, $p=0.003$), presence of concomitant DM ($r=0.134$, $p=0.047$), cardiac arrhythmias ($r=0.156$, $p=0.022$) and myocardial impaired relaxation ($r=0.241$, $p=0.037$).

The authors have also advised that there is an error in Table 2 on page 1001 of the published article. In the upper section of the table “Hypertension complications”, the column containing absolute numbers (n_1) was inadvertently shifted, and the values were incorrectly displayed under the percentage (%) column. As a result, the frequencies of individual complications were misrepresented. This error does not affect the results described in the main text or the conclusions of the study. The correct Table 2 is as follows.

Table 2 The Most Common Complications of HP and Treatment Modalities of HP and DM in the Studied Cohort (Absolute Numbers, %).

Characteristics	n	n_1	%
Hypertension complications:	427	103	24.1
History of transient ischemic attack		9	2.1
History of ischemic stroke		26	6.1
History of myocardial infarction		18	4.2
History of cardiac arrhythmias, including:		35	8.2
(Paroxysmal atrial fibrillation)		(13)	(3.0)
(Permanent atrial fibrillation)		(11)	(2.6)
Aortic ectasia /aneurysm		11	2.6
Others (eg. retinal hemorrhage)		4	0.9
Hypertension treatment:	427		
Regular/systematic		283	66.3
Episodic		71	16.6
No treatment		65	15.1
Information unavailable		8	1.9
Most commonly used pharmacological groups of antihypertensive drugs:	427		
ACEIs regularly		142	33.25
ARBs regularly		92	21.54

(Continued)



Table 2 (Continued).

Characteristics	n	n ₁	%
ACEIs episodically		41	9.60
ARBs episodically		8	1.87
Diuretics regularly		163	38.17
Diuretics episodically		27	6.23
CCBs regularly		76	17.80
CCBs episodically		10	2.34
Beta-blockers regularly		118	27.63
Beta-blockers episodically		18	4.215
Diabetes mellitus treatment:	105		
Oral hypoglycemics regularly		74	70.48
Insulin preparations		18	17.14
Do not take anti-diabetic drugs		13	12.38

Notes: n – total available data. n₁ – absolute number of observations.

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers.

The authors would like to apologize for any inconvenience caused by these oversights.

Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

Dovepress
Taylor & Francis Group